

Supporting Information

Asymmetric Synthesis of Trifluoromethylated Allylic Amines Using α,β -Unsaturated *N*-*tert*-Butanesulfinimines

G. K. Surya Prakash*, Mihirbaran Mandal, and George A. Olah*

Donald P. and Katherine B. Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, University Park, Los Angeles, California 90089-1661
gprakash@usc.edu

3a: (*R*)-(-)-*N*-(3-phenyl-allylidene)-2-methylpropanesulfinamide: Yield 90%. $[\alpha]_D^{20}$ -289 (*c* 3.7, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.23 (9H, s), 7.08 (1H, dd, *J* = 15.7 Hz, *J* = 9.04 Hz), 7.22 (1H, d, *J* = 15.7 Hz), 7.38 (3H, m), 7.53 (2H, m), 8.37 (1H, d, *J* = 9.07 Hz). ¹³C NMR (125 MHz, CDCl₃): δ 22.3, 55.4, 125.5, 127.8, 128.8, 130, 134.9, 146.2, 163.6.

3b: (*R*)-(-)-*N*-(2-methyl-3-phenyl-allylidene)-2-methylpropanesulfinamide: Yield 87%. $[\alpha]_D^{20}$ -406 (*c* 0.99, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.24 (9H, s), 2.20 (3H, s), 7.11 (1H, s), 7.32 – 7.47 (5H, m), 8.30 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 13.0, 22.5, 57.4, 128.5, 127.6, 129.7, 135.2, 135.9, 144.0, 167.

3c: (*R*)-(-)-*N*-(3-furyl-allylidene)-2-methylpropanesulfinamide: Yield 85%. $[\alpha]_D^{20}$ -265 (*c* 1.2, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.22 (9H, s), 6.49 (1H, m), 6.63 (1H, d, *J* = 3.23 Hz), 6.97 (2H, m), 7.51 (1H, s), 8.30 (1H, d, *J* = 7.9 Hz). ¹³C NMR (125 MHz, CDCl₃): δ 22.4, 57.5, 112.4, 114.3, 123.5, 131.9, 144.7, 151.3, 162.9.

3d: (*R*)-(-)-*N*-(3-furyl-2-methyl-allylidene)-2-methylpropanesulfinamide: Yield 83%. ¹H NMR (500 MHz, CDCl₃): δ 1.22 (9H, s), 2.26 (3H, s), 6.52 (1H, m), 6.65 (1H, d, *J* = 3.46 Hz), 6.84 (1H, s), 7.56 (1H, m), 8.22 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 12.8, 22.4, 57.4, 112.2, 114.8, 130.0, 132.3, 144.2, 152.1, 165.9.

3e: (R)-(-)-N-(3,3-diphenyl-allylidene)-2-methylpropanesulfinamide: Yield 80%. $[\alpha]_D^{20}$ - 488 (*c* 1.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.22 (9H, s), 7.01 (1H, d, *J* = 9.75 Hz), 7.21 – 7.41 (5H, m), 8.30 (1H, d, *J* = 9.8 Hz). ¹³C NMR (125 MHz, CDCl₃): δ 22.5, 57.5, 124.4, 128.4, 128.5, 128.9, 129.5, 130.4, 137.4, 140.6, 156.3, 162.3

3f: (R)-(-)-N-(2-pentyl-3-phenyl-allylidene)-2-methylpropanesulfinamide: Yield 75%. $[\alpha]_D^{20}$ - 231 (*c* 4.5, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.89 (3H, t, *J* = 6.97 Hz), 1.24 (9H, s), 1.36 (4H, m), 1.59 (2H, m), 2.64 (2H, m), 7.06 (1H, s), 7.32 – 7.43 (5H, m), 8.30 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.3, 26.6, 28.1, 32.0, 57.4, 128.5, 128.6, 129.3, 135.8, 140.1, 143.9, 166.8.

3g: (R)-(-)-N-(2-hexyl-3-phenyl-allylidene)-2-methylpropanesulfinamide: Yield 70%. $[\alpha]_D^{20}$ - 233 (*c* 4.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.88 (3H, t, *J* = 6.97 Hz), 1.24 (9H, s), 1.30 (4H, m), 1.39 (2H, m), 1.58 (2H, m), 2.64 (2H, m), 7.05 (1H, s), 7.32 – 7.43 (5H, m), 8.23 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.6, 28.4, 29.5, 31.4, 57.3, 128.5, 128.6, 129.3, 135.7, 140.1, 143.9, 166.8.

3h: (R)-(-)-N-(2,3-diphenyl-allylidene)-2-methylpropanesulfinamide: Yield 86%. $[\alpha]_D^{20}$ - 473 (*c* 0.96, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.21 (9H, s), 7.35 – 7.48 (11H, m), 8.88 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 22.6, 57.7, 127.9, 128.6, 129.0, 129.1, 129.9, 134.9, 138.0, 143.2, 161.6.

4a: (R_S, S)-(-)-N-(3-phenyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_D^{20}$ - 27.3 (*c* 0.66, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.27 (9H, s), 3.47 (1H, d, *J* = 8.2 Hz), 4.47 (1H, m), 6.21 (1H, dd, *J* = 15.8 Hz, *J* = 6.0 Hz), 6.91 (1H, d, *J* = 15.8 Hz), 7.29-7.43 (5H, m). ¹³C NMR (125 MHz, CDCl₃): δ 22.3, 57.0, 60.4 (q, ²*J*_{C-F} = 31.0 Hz), 120.1, 124.6 (q, ¹*J*_{C-F} = 281 Hz), 127.0, 128.6, 128.7, 135.2, 137.2. ¹⁹F NMR (500 MHz, CDCl₃): δ = -76.3 (d, *J*_{F-H} = 9.6 Hz).

4b: (*R_S*, *S*)-(-)-*N*-(2-methyl-3-phenyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_D^{20} - 66.1$ (*c* 1.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.26 (9H, s), 1.96 (3H, s), 3.67 (1H, d, *J* = 8.3 Hz), 4.32 (1H, m), 6.70 (1H, s), 7.24-7.36 (5H, m); ¹³C NMR (125 MHz, CDCl₃): δ 14.6, 22.0, 56.9, 65.1 (q, ²*J*_{C-F} = 27.6 Hz), 124.7 (q, ¹*J*_{C-F} = 282 Hz), 127.3, 128.2, 129.0, 130.4, 132.8, 136.0; ¹⁹F NMR (500 MHz, CDCl₃): δ = -73.4 (d, *J*_{F-H} = 7.5 Hz).

4c: (*R_S*, *S*)-(-)-*N*-(3-furyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_D^{20} - 19.6$ (*c* 3.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.24 (9H, s), 3.54 (1H, d, *J* = 8.1 Hz), 4.43 (1H, m), 6.17 (1H, dd, *J* = 15.8 Hz, *J* = 6.6 Hz), 6.37 (2H, m), 6.72 (1H, d, *J* = 15.8 Hz), 7.37 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 22.4, 57.0, 60.2 ((q, ²*J*_{C-F} = 28.7 Hz), 110.6, 111.5, 118.4, 124.5 (q, ¹*J*_{C-F} = 280 Hz), 124.8, 142.9, 151.0; ¹⁹F NMR (500 MHz, CDCl₃): δ = -76.4 (d, *J*_{F-H} = 7.6 Hz).

4d: (*R_S*, *S*)-(-)-*N*-(3-furyl-2-methyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_D^{20} - 61.6$ (*c* 1.5, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.25 (s, 9H), 2.12 (s, 3H), 3.61 (d, 1H, *J* = 8.3 Hz), 4.26 (1H, m), 6.36-6.44 (3H, m), 7.42 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 15.5, 22.3, 57.0, 65.0 (q, ²*J*_{C-F} = 31.0 Hz), 111.3, 111.4, 121.8, 124.6 (q, ¹*J*_{C-F} = 282 Hz), 127.4, 142.3, 151.5; ¹⁹F NMR (500 MHz, CDCl₃): δ = -73.5 (d, *J*_{F-H} = 6.8 Hz).

4e: (*R_S*, *S*)-(-)-*N*-(3,3-diphenyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_D^{20} - 88.7$ (*c* 0.98, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 1.19 (9H, s), 3.44 (1H, d, *J* = 7.4 Hz), 4.39 (1H, m), 6.01 (1H, d, *J* = 9.8 Hz), 7.25-7.47 (10H, m); ¹³C NMR (125 MHz, CDCl₃): δ 22.3, 57.0, 58.0 (q, ²*J*_{C-F} = 29.6 Hz), 118.6, 124.7 (q, ¹*J*_{C-F} = 282 Hz), 127.7, 128.1, 128.3, 128.5, 128.7, 129.5, 138.0, 140.6, 149.6; ¹⁹F NMR (500 MHz, CDCl₃): δ = -75.8 (d, *J*_{F-H} = 6.7 Hz).

4f: (*R_S*, *S*)-(-)-*N*-(2-pentyl-3-phenyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_D^{20} - 55.8$ (*c* 0.98, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 0.86 (3H, m), 1.27

(13H, m), 1.54 (2H, m), 2.28-2.42 (2H, m), 3.52 (1H, d, $J = 6.6$ Hz), 4.29 (1H, m), 6.72 (1H, s), 7.23-7.36 (5H, m): ^{13}C NMR (125 MHz, CDCl_3): δ 13.9, 22.2, 23.0, 27.8, 30.7, 31.8, 56.9, 61.7 (q, $^2J_{\text{C-F}} = 30.9$ Hz), 124.8 (q, $^1J_{\text{C-F}} = 280$ Hz), 127.4, 128.3, 128.6, 131.2, 136.2, 136.9: ^{19}F NMR (500 MHz, CDCl_3): $\delta = -73.5$ (d, $J_{\text{F-H}} = 9.3$ Hz).

4g: (*R*_S, *S*)-(-)-*N*-(2-hexyl-3-phenyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_{\text{D}}^{20} - 59.1$ (c 1.0, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ 0.85 (3H, t, $J = 7.0$ Hz), 1.27 (15H, m), 1.53 (2H, m), 2.28-2.42 (2H, m), 3.52 (1H, d, $J = 6.5$ Hz), 4.28 (1H, m), 6.71 (1H, s), 7.23-7.36 (5H, m): ^{13}C NMR (125 MHz, CDCl_3): δ 13.9, 22.4, 22.5, 28.0, 29.2, 30.4, 31.4, 56.8, 61 (q, $^2J_{\text{C-F}} = 29.7$ Hz), 124.8 (q, $^1J_{\text{C-F}} = 281$ Hz), 127.4, 128.3, 128.6, 131.2, 136.2, 136.8. ^{19}F NMR (500 MHz, CDCl_3): $\delta = -73.6$ (d, $J_{\text{F-H}} = 7.4$ Hz).

4h: (*R*_S, *S*)-(-)-*N*-(2,3-diphenyl-1-trifluoromethyl-allyl)-2-methylpropanesulfinamide: $[\alpha]_{\text{D}}^{20} - 152$ (c 1.0, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ 1.14 (9H, s), 3.77 (1H, d, $J = 10.3$ Hz), 5.01 (1H, m), 6.85 (1H, s), 7.35 - 7.46 (10H, m): ^{13}C NMR (125 MHz, CDCl_3): δ 22.3, 56.9, 58.7 (q, $^2J_{\text{C-F}} = 30.7$ Hz), 124.6 (q, $^1J_{\text{C-F}} = 282$ Hz), 127.8, 128.0, 128.3, 128.6, 128.8, 130.3, 135.7, 135.8, 136.9, 137.7: ^{19}F NMR (500 MHz, CDCl_3): $\delta = -71.6$ (d, $J_{\text{F-H}} = 7.83$ Hz).

6: (*S*)-(+)-3-phenyl-1-trifluoromethyl allylamine hydrochloride: $[\alpha]_{\text{D}}^{20} + 51.4$ (c 1.0, CH_3OH). ^1H NMR (360 MHz, CD_3OD): δ 6.20 (1H, dd, $J = 15.9$ Hz, $J = 8.7$ Hz), 7.10 (1H, d, $J = 15.7$ Hz), 7.38 (3H, m), 7.52 (2H, m): ^{13}C NMR (90 MHz, CD_3OD): δ 55.7 (q, $^2J_{\text{C-F}} = 32.8$ Hz), 115.0, 124.7 (q, $^1J_{\text{C-F}} = 279$ Hz), 128.3, 129.9, 130.7, 135.8, 142.9: ^{19}F NMR (360 MHz, CD_3OD): $\delta = -73.8$ (d, $J_{\text{F-H}} = 5.03$ Hz).